touchROUNDTABLE
Finding the target in METex14 skipping NSCLC – optimizing patient benefit through best practice
Learning Objectives
After watching this activity, participants should be better able to:
- Discuss the complex landscape of biomarker testing for NSCLC in the advanced setting
- Describe the recently-published near-global consensus statements on diagnostic best practice in METex14 skipping NSCLC
- Discuss how optimizing testing and diagnosis can aid treatment decisions, improve patient selection, and benefit patients through early initiation of targeted therapy
- Provide an overview of the current treatment landscape in METex14 skipping NSCLC, and discuss the challenges oncologists and pathologists face in its diagnosis and management
Overview
Non small cell lung cancer (NSCLC) is a heterogeneous disease with many molecular subtypes and oncogenic driver mutations.1-3 One aggressive NSCLC subtype with a poor prognosis is driven by Mesenchymal Epithelial Transition exon 14 (METex14) skipping mutations. Effective targeted therapies for METex14 skipping NSCLC are available.1 However, accurate identification of the disease requires comprehensive molecular testing,3 and standardized diagnostic guidelines implementing this approach are not currently available.1,3 In this activity, watch leading oncology experts discuss recent consensus statements from near-global groups on the diagnosis, testing, and management of METex14 skipping NSCLC, and the implications they may have for clinical practice.
References
- Ahn M-J, et al. Asian Thoracic Oncology Research Group (ATORG) expert consensus statement on MET alterations in NSCLC: Diagnostic and therapeutic considerations. Clin Lung Cancer. 2022;23:670–685.
- Mahrous M, et al. Consensus recommendations for the diagnosis, biomarker testing, and clinical management of advanced or metastatic non-small cell lung cancer with mesenchymal-epithelial transition exon 14 skipping mutations in the Middle East, Africa, and Russia. 2023;15:e41992.
- Malapelle U, et al. Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer. Br J Cancer. 2024;131:212–219.
- Downloads including slides are available for this activity in the Toolkit
Faculty information is located in the Toolkit.
- Downloads including slides are available for this activity in the Toolkit
Faculty information is located in the Toolkit.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
